FA
NTLA icon

FDx Advisors’s Intellia Therapeutics NTLA Stock Holding History

FDx Advisors’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-10,321
Closed -$315K – 552
2023
Q4 		$315K Sell
10,321
-255
-2% -$7.33K 0.02% 514
2023
Q3 		$334K Sell
10,576
-6,036
-36% -$234K 0.03% 443
2023
Q2 		$677K Buy
16,612
+2,762
+20% +$112K 0.04% 380
2023
Q1 		$483K Hold
13,850
– – 0.02% 423
2022
Q4 		$483K Buy
13,850
+156
+1% +$7.42K 0.02% 423
2022
Q3 		$766K Buy
13,694
+1,164
+9% +$72.2K 0.03% 324
2022
Q2 		$649K Buy
12,530
+2,419
+24% +$123K 0.02% 408
2022
Q1 		$735K Sell
10,111
-13
-0.1% -$1.1K 0.02% 399
2021
Q4 		$1.2M Buy
10,124
+26
+0.3% +$3.26K 0.03% 326
2021
Q3 		$1.35M Sell
10,098
-1,969
-16% -$298K 0.04% 285
2021
Q2 		$1.95M Sell
12,067
-7,296
-38% -$568K 0.06% 203
2021
Q1 		$1.55M Sell
19,363
-3,046
-14% -$204K 0.06% 205
2020
Q4 		$1.22M Buy
22,409
+513
+2% +$18.6K 0.05% 231
2020
Q3 		$435K Buy
21,896
+9,824
+81% +$205K 0.02% 409
2020
Q2 		$254K Buy
+12,072
New +$205K 0.01% 478

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

FDx Advisors's NTLA Position: Q1 2024 in Review

FDx Advisors sold out of Intellia Therapeutics (NTLA) in Q1 2024, closing a stake of 10,321 shares — an estimated $315K sold.

FDx Advisors first reported a position in NTLA in Q2 2020 and held it in 15 quarters. The position peaked at $1.95M in Q2 2021. 284 funds tracked by Wall St. Rank hold NTLA as of Q1 2024.

  • FDx Advisors reported no remaining Intellia Therapeutics position as of Q1 2024 after selling out during the quarter.
  • FDx Advisors sold 10,321 Intellia Therapeutics shares in Q1 2024, an estimated $315K.
  • FDx Advisors first reported a position in Intellia Therapeutics in Q2 2020 and held it in 15 quarters.
  • FDx Advisors's Intellia Therapeutics position peaked at $1.95M in Q2 2021.
  • 284 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q1 2024.

Based on FDx Advisors's 13F filing for Q1 2024, filed 3 May 2024.